Addiction medicine professionals have important role in reducing public health problems due to substance use and addictions which goes beyond clinical practice in specialized services. Currently WHO is revising International Classification of Diseases (ICD), and ICD-11 is expected to be released in 2017. Clinical and health care utility is in the forefront of ICD revision. The current draft of ICD-11 maintains the diagnostic categories of "dependence" and "harmful use" with expanded boundaries of the concept of "harmful use". Field testing of ICD-11 requires active participation of professional associations and practitioners from different parts of the world.
VOLUME 6 NO. 1
23

CJA JCA
Addiction medicine professionals have important role in reducing public health problems due to substance use and addictions which goes beyond clinical practice in specialized services. Currently WHO is revising International Classification of Diseases (ICD), and ICD-11 is expected to be released in 2017. Clinical and health care utility is in the forefront of ICD revision. The current draft of ICD-11 maintains the diagnostic categories of "dependence" and "harmful use" with expanded boundaries of the concept of "harmful use". Field testing of ICD-11 requires active participation of professional associations and practitioners from different parts of the world.
STRESS AND ADDICTIONS: NEUROBIOLOGIC INTERFACE
Kathleen T. Brady
Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, USA
The relationship between stress and addictions is complex. Early life adversity is a well-known risk factor for the development of addiction and stress is associated with relapse vulnerability. Preclinical research demonstrates that stress exposure enhances drug self-administration and reinstates drug seeking in drug-experienced animals. There are common neurobiologic systems involved in the stress response and in addictions including corticotropin releasing factor, the hypothalamic-pituitary adrenal axis (CRF/HPA), extrahypothalamic CRFand noradrenergic systems. In this presentation, neurobiologic relationships at the interface of stress and addictions and treatment implications will be explored.
MECHANISMS AND TREATMENT OF BEHAVIORAL ADDICTIONS WITH SPECIAL EMPHASIS ON INTERNET AND FOOD ADDICTIONS
Marc N. Potenza
Yale University School of Medicine, USA Background: The extent to which excessive engagement in non-substance-related behaviors may constitute addictions has been debated. The recent classification of gambling disorder together with substance-use disorders in DSM-5 was based on similarities between the disorders and lends additional credence to the concept of nonsubstance or behavioral addictions.
Methods: Data will be presented from studies into the biological underpinnings of substance-use and nonsubstance-use disorders involving excessive patterns of gambling, eating, Internet use, sex and other behaviors. Data from randomized clinical trials will be presented.
Results: Gambling disorder is arguably the best studied of the behavioral addictions to date. Data indicate multiple similarities, as well as differences, between gambling disorder and substance-use disorders. Considerable debate exists as to whether obesity of other eating-related disorders might be best considered within an addiction framework, with data suggesting particular similarities between gambling, substance-use and binge-eating disorders. Although less data exist for excessive engagement in other behaviors (Internet use, sex), emerging data suggest similarities with substance-use disorders. Given biological similarities, a question arises as to whether behavioral and pharmacological treatments efficacious in the treatment of substance addictions might prove helpful in the treatment of behavioral addictions, with data providing support for cognitive-behavioral therapies and opioidergic and glutamatergic agents.
Conclusions: An improved understanding of the biological factors underlying behavioral addictions is developing, and this understanding should lead to the greater availability of validated therapies.
